RSL3 is the inhibitor of the glutathione (GSH) peroxidase 4, which can inhibit the cysteine/glutamate amino acid transporter system. RSL3 blocks GSH synthesis with an IC50 of 100 nM. RSL3, that are synthetically lethal with cell lines expressing mutant HRAS and KRAS1.
Oncogene. 2021 Mar;40(9):1706-1720.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO: ≥ 30 mg/mL|
|Related Ferroptosis Products|
IFSP1 is an effective, selective and glutathione-independent inhibitor of ferroptosis Suppressor protein 1 (FSP1/AIFM2) with an EC50 value of 103 nM. IFSP1 can selectively induce iron death in Pfa1 cells and HT1080 cells with GPX4 knockout gene overexpressing FSP1.
SRS16-86 is a potent inhibitor of ferroptosis. SRS16-86 is more metabolically and plasma-stable in vivo than Ferrostatin-1. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) studies.
UAMC-3203 is an improved ferroptosis inhibitor, with an IC50 value of 10 nM in IMR-32 neuroblastoma cells.
ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor that induces iron death and has shown cytotoxic effects against melanoma, lung adenocarcinoma, fibrosarcoma, and pancreatic cancer cell lines.
JKE-1674 is an inhibitor of glutathione peroxidase 4 (GPX4) and an active metabolite of the GPX4 inhibitor ML-210. JKE-1674 reduces viability of LOX-IMVI cancer cells and in a panel of additional cancer cell lines, an effect that can be blocked by the ferroptosis inhibitor ferrostatin-1.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.